The impact of CYP3A5*1/*3, PIA1/A2 and T744C polymorphisms on clopidogrel and acetylsalicylic acid response variability in Mexican population.

@article{IsordiaSalas2012TheIO,
  title={The impact of CYP3A5*1/*3, PIA1/A2 and T744C polymorphisms on clopidogrel and acetylsalicylic acid response variability in Mexican population.},
  author={Irma Isordia-Salas and Marcos Jaciel Olalde-Rom{\'a}n and David Santiago-Germ{\'a}n and Norma Corona de la Pe{\~n}a and Jes{\'u}s Salvador Valencia-S{\'a}nchez},
  journal={Thrombosis research},
  year={2012},
  volume={130 3},
  pages={e67-72}
}
INTRODUCTION Clopidogrel is recommended in addition to aspirin to prevent atherothrombotic events in patients with acute coronary syndromes (ACS) and in those undergoing percutaneous coronary intervention (PCI). However, an interindividual variability in platelet inhibition response to clopidogrel has been demonstrated, and is associated with recurrent cardiovascular events. Multiple mechanisms have been associated with no response including genetics factors. MATERIALS AND METHODS The present… CONTINUE READING